Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

it would be a prospective cohort study. According to BMI, all the women, aged\>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obese Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

obese female Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers Adiponectin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

losartan

losartan, 100mg daily,

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetic nephropathy
* CKD at stage 1\~4

Exclusion Criteria

* Type 1 diabetes or nondiabetic renal disease
* An elevated plasma K level.

Minimum Eligible Age

30 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

hui min Jin, MD

Role: PRINCIPAL_INVESTIGATOR

shanghai No 3 people's hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADL

Identifier Type: -

Identifier Source: org_study_id